XORTX Therapeutics Inc. is a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease. The company is actively involved in creating ...
XORTX Therapeutics (XRTX) announces the launch of a new late stage program to treat gout. The new drug development program – XRx-026 – will ...
XORTX to focus on late stage allopurinol intolerant gout program; discussion with FDA planned for first half 2025 regarding ...
and tolerability of serum uric acid lowering and maintenance with febuxostat in patients with gout. Febuxostat Open-label Clinical Trial of Urate-lowering Efficacy and Safety Adverse events were ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback